Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8206 to 8213 of 8213 results

  1. NICE launches second consultation on genetic testing to guide treatment after a stroke

    People could be offered a genetic test in the immediate period after having a stroke to help identify the most suitable treatment to reduce their risk of further strokes.

  2. Introducing a new way of prioritising our guidance topics

    NICE's deputy chief executive, Jonathan Benger, talks about our new approach to prioritisation.

  3. How NICE is ensuring its topic prioritisation decisions are grounded in lived experience

    Simon Denegri discusses NICE’s commitment to involving the public voice in its work and decisions.

  4. NICE collaboration on streamlined licensing and patient access process for new medicines

    Companies can now submit medicines for the new Innovative Licensing and Access Pathway (ILAP) following close collaboration between the NICE, drug regulators, the NHS and equivalent organisations in Scotland.

  5. Pembrolizumab plus chemotherapy not recommend for triple negative breast cancer

    Draft guidance published today (8 March 2022) by NICE does not recommend pembrolizumab plus chemotherapy for treating triple negative breast cancer

  6. How NICE manages the potential conflicts of interests of patient experts

    People with lived experience provide valuable insight into the impact of NICE’s’ guidance and advice.

  7. Women inspiring inclusion in NICE guidance

    This International Women’s Day, we’re focusing on the invaluable contributions of 2 of the women who help shape our guidance through their independent voluntary committee roles. They talk to us about their involvement with NICE and what #InspireInclusion means to them.

  8. NICE joins the shared commitment to public involvement in research

    Working alongside people and communities is an essential tool in helping to improve?the impact of our guidance and continuing to get the best care to people and communities, fast, while ensuring value for the taxpayer.